<DOC>
	<DOCNO>NCT02738775</DOCNO>
	<brief_summary>This study evaluate use single agent ublituximab , novel monoclonal antibody , patient relapse form multiple sclerosis</brief_summary>
	<brief_title>Phase 2 Study Ublituximab Patients With Relapsing Forms Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>Diagnosis relapse multiple sclerosis Active disease Greater 1 relapse prior 2 year Treatment antiCD20 monoclonal antibody within last 12 month Treatment alemtuzumab within last 12 month Pregnant nursing mother</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>multiple sclerosis</keyword>
</DOC>